[Editorial Analysis] The cost of haste: On drugs, vaccines and regulators

Mains Paper 2: Health
Prelims level: SARS-CoV-2
Mains level: Issues relating to development and management of Social Sector/Services relating to Health


• So far-reaching are the effects of COVID-19 that it has harried drug regulatory authorities, usually the most risk-averse within the bureaucracy.

• ‘Do no harm’ is the driving principle of drug regulation and this is reflected in the thicket of documents and permissions that stand before the average novel drug or vaccine.

• However, SARS-CoV-2, while mostly non-lethal, kills across demography and age-groups to confound sophisticated care systems.


• This has sent a signal to drug companies, biomedical firms and governments to scramble for anything with even the slightest chance of success.

• It is in this context that regulators, used to long timelines of testing new vaccines or drugs, are now under pressure to
facilitate a solution.

• Usually the regulators stick to weighing and dwelling on evidence of efficacy and safety.

• India’s drug regulatory authority as well as the Department of Biotechnology, which also funds vaccine development and drug research, now collaborate on fast-tracking.

• For instance, if an Indian company has partnered with a foreign one in developing a vaccine, then any trials already conducted by the foreign unit would be considered in allowing Indian companies to avoid repeating them in India.

• For drugs, those that have been proven to be safe for treating one disease may skip a fresh, large human trial, or a phase-3 trial.

• Potential vaccines too are now allowed to combine stages of trials — normally, regulators must approve results of each stage — to permit those testing the drug to move to the next stage.

• The rush to compress timelines, in itself, is no guarantee that a workable vaccine or reliable drug will emerge any faster.

• Drugs and vaccine-development have historically been expensive because immunology is a complex, eternal struggle with disease, and with high failures.

Emergency use:

• There have been instances when disease mortality is so high that not offering even a half-baked drug or a vaccine would be unethical.

• That is a call regulators have to constantly take. But not all emergencies are the same.

• There is now a situation, as in the case of itolizumab, a psoriasis drug repurposed for COVID-19, where the drug regulator has approved it for emergency use but the COVID-19 task force has expressed its reservations.

• Such dissonance among experts is unacceptable especially when they all have access to the same evidence.

• There is a tendency to view COVID-19 vaccine development or a new drug as a ‘race’ in which only the first vaccine to be out matters.

• Historically, vaccines, even those targeting the same disease, only get better over time.


• Will COVID-19 continuously linger as an endemic disease or will it mutate into oblivion.

• If it is the former, scientists can continue to work on better drugs or improved vaccines. Haste does not aid science.

• Regulators of drugs and vaccines should not have to sign off on low-pass filters.


Prelims Questions:

Q.1) Which of the following hospital has started a video-consultation program with ICU doctors across the country called e-ICU?

(a) AIIMS New Delhi
(b) Sir Ganga Ram Hospital
(c) Apollo New Delhi
(d) None of the above

Answer: A

Mains Questions:

Q.1) Regulators of drugs and vaccines should not have to sign off on low-pass filters. Critically examine the statement.

Subscribe to Get Weekly updates

Get daily current affair video, detailed current affairs PPT for quick revision and Free One Liner PDF directly in your inbox. Subscribe now to get this month's one liner for FREE.